Abstract
Background The novel coronavirus: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly throughout the world leading to catastrophic consequences. However, SARS-CoV-2 infection has shown discernible variability across the globe. While in some countries people are recovering relatively quickly, in others, recovery times have been comparatively longer and number of individuals succumbing to it are high. This variability in coronavirus disease 2019 (COVID-19) susceptibility is suggestive of a likely association between the genetic make up of affected individuals modulated by their ancestry and the severity of COVID-19 manifestations. Objective In this study, we aimed to evaluate the potential association between an individual's genetic ancestry and the extent of COVID-19 disease presentation employing Europeans as the case study. In addition, using a genome wide association (GWAS) approach we sought to discern the putative single nucleotide polymorphism (SNP) markers and genes that may be likely associated with differential COVID-19 manifestations by comparative analyses of the European and East Asian genomes. Method To this end, we employed 10,215 ancient and modern genomes across the globe assessing 597,573 SNPs obtained from the databank of Dr. David Reich, Harvard Medical School, USA to evaluate the likely correlation between European ancestry and COVID-19 manifestations. Ancestry proportions were determined using qpAdm program implemented in AdmixTools v5.1. Pearson's correlation coefficient (r) between various ancestry proportions of European genomes and COVID-19 death/recovery ratio was calculated and its significance was statistically evaluated. Genome wide association study (GWAS) was performed in PLINK v1.9 to investigate SNPs with significant allele frequency variations among European and East Asian genomes that likely correlated with differential COVID-19 infectivity. Results We found significant positive correlation (r=0.58, P=0.03) between West European hunter gatherers (WHG) ancestral fractions and COVID-19 death/recovery ratio for data as of 5th April 2020. This association discernibly amplified (r=0.77, P=0.009) upon reanalyses based on data as of 30th June 2020, removing countries with small sample sizes and adding those that are a bridge between Europe and Asia. Using GWAS we further identified 404 immune response related SNPs by comparing publicly available 753 genomes from various European countries against 838 genomes from various Eastern Asian countries. Prominently, we identified that SNPs associated with immune-system related pathways such as interferon stimulated antiviral response, adaptive and innate immune system and IL-6 dependent immune responses show significant differences in allele frequencies [Chi square values (Chi square values >1500; P=0)] between Europeans and East Asians. Conclusion So far, to the best of our knowledge, this is the first study investigating the likely association between host genetic ancestry and COVID-19 severity. These findings improve our overall understanding of the putative genetic modifiers of COVID-19 clinical presentation. We note that the development of effective therapeutics will benefit immensely from more detailed analyses of individual genomic sequence data from COVID-19 patients of varied ancestries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was required for this study.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The manuscript has been revised with update data. New figures added.
Data Availability
The current study employed publicly available data, which is freely available through the database of Dr. David Reich, Harvard Medical School (https://reich.hms.harvard.edu/datasets).
